This article has been reviewed according to Science X's editorial process and policies. Editors have highlighted the following attributes while ensuring the content's credibility:

fact-checked

peer-reviewed publication

reputable news agency

proofread

Adjuvant alectinib improves disease-free survival in lung cancer

Adjuvant alectinib improves disease-free survival in lung cancer

Adjuvant alectinib improves disease-free survival compared with platinum-based chemotherapy among patients with resected ALK-positive non-small cell lung cancer (NSCLC), according to a study published in the April 11 issue of the New England Journal of Medicine.

Yi-Long Wu, M.D., from the Guangdong Lung Cancer Institute in Guangzhou, China, and colleagues conducted a global, phase 3, open-label, randomized trial involving patients with completely resected, ALK-positive NSCLC of stage IB, II, or IIIA. Participants were randomly assigned to receive oral alectinib (600 mg twice daily) for 24 months or intravenous in four 21-day cycles (130 and 127 patients, respectively).

The researchers found that the percentage of patients alive and disease-free was 93.8 and 63.0 percent in the alectinib and chemotherapy groups, respectively, at two years, among patients with stage II or IIIA disease (hazard ratio for or death, 0.24), and 93.6 and 63.7 percent, respectively, in the intention-to-treat population (hazard ratio, 0.24). A clinically meaningful benefit with respect to central nervous system was seen in association with alectinib versus chemotherapy (hazard ratio, 0.22). The overall survival data were immature. There were no unexpected safety findings.

"The disease-free survival benefit was seen consistently across prespecified subgroups, including those defined according to disease stage, race, sex, and smoking status," the authors write.

The study was funded by F. Hoffmann-La Roche, the manufacturer of alectinib.

More information: Yi-Long Wu et al, Alectinib in Resected ALK -Positive Non–Small-Cell Lung Cancer, New England Journal of Medicine (2024). DOI: 10.1056/NEJMoa2310532

Antonio Passaro et al, Adjuvant Alectinib in ALK -Rearranged NSCLC — Here and Now, New England Journal of Medicine (2024). DOI: 10.1056/NEJMe2402015

Journal information: New England Journal of Medicine

Copyright © 2024 HealthDay. All rights reserved.

Citation: Adjuvant alectinib improves disease-free survival in lung cancer (2024, April 13) retrieved 26 May 2024 from https://medicalxpress.com/news/2024-04-adjuvant-alectinib-disease-free-survival.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.

Explore further

AACR: Cadonilimab plus chemo beneficial for gastric adenocarcinoma

1 shares

Feedback to editors